BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37543673)

  • 1. IL-1β transgenic mouse model of inflammation driven esophageal and oral squamous cell carcinoma.
    Muthupalani S; Annamalai D; Feng Y; Ganesan SM; Ge Z; Whary MT; Nakagawa H; Rustgi AK; Wang TC; Fox JG
    Sci Rep; 2023 Aug; 13(1):12732. PubMed ID: 37543673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immature myeloid progenitors promote disease progression in a mouse model of Barrett's-like metaplasia.
    Kong J; Sai H; Crissey MA; Jhala N; Falk GW; Ginsberg GG; Abrams JA; Nakagawa H; Wang K; Rustgi AK; Wang TC; Lynch JP
    Oncotarget; 2015 Oct; 6(32):32980-3005. PubMed ID: 26460825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomere shortening accelerates tumor initiation in the L2-IL1B mouse model of Barrett esophagus and emerges as a possible biomarker.
    Sahm V; Maurer C; Baumeister T; Anand A; Strangmann J; Schmid RM; Wang TC; Quante M
    Oncotarget; 2022; 13():347-359. PubMed ID: 35178191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via Interleukin 8 and Alterations to the Gut Microbiome.
    Münch NS; Fang HY; Ingermann J; Maurer HC; Anand A; Kellner V; Sahm V; Wiethaler M; Baumeister T; Wein F; Einwächter H; Bolze F; Klingenspor M; Haller D; Kavanagh M; Lysaght J; Friedman R; Dannenberg AJ; Pollak M; Holt PR; Muthupalani S; Fox JG; Whary MT; Lee Y; Ren TY; Elliot R; Fitzgerald R; Steiger K; Schmid RM; Wang TC; Quante M
    Gastroenterology; 2019 Aug; 157(2):492-506.e2. PubMed ID: 30998992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma.
    Kunze B; Wein F; Fang HY; Anand A; Baumeister T; Strangmann J; Gerland S; Ingermann J; Münch NS; Wiethaler M; Sahm V; Hidalgo-Sastre A; Lange S; Lightdale CJ; Bokhari A; Falk GW; Friedman RA; Ginsberg GG; Iyer PG; Jin Z; Nakagawa H; Shawber CJ; Nguyen T; Raab WJ; Dalerba P; Rustgi AK; Sepulveda AR; Wang KK; Schmid RM; Wang TC; Abrams JA; Quante M
    Gastroenterology; 2020 Aug; 159(2):575-590. PubMed ID: 32325086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus.
    Lee Y; Urbanska AM; Hayakawa Y; Wang H; Au AS; Luna AM; Chang W; Jin G; Bhagat G; Abrams JA; Friedman RA; Varro A; Wang KK; Boyce M; Rustgi AK; Sepulveda AR; Quante M; Wang TC
    Oncotarget; 2017 Jan; 8(1):203-214. PubMed ID: 27448962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid droplet biogenesis and COX-2 pathway activation are triggered by Barrett's esophagus and adenocarcinoma, but not esophageal squamous cell carcinoma risk factors.
    Carrossini N; Meireles Da Costa N; Andrade-Barreto E; Sousa VPL; Nicolau-Neto P; Souza-Santos PT; Mansur GR; Wernersbach L; Bozza PT; Viola JPB; Ribeiro Pinto LF
    Sci Rep; 2021 Jan; 11(1):981. PubMed ID: 33441691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma.
    Derks S; Nason KS; Liao X; Stachler MD; Liu KX; Liu JB; Sicinska E; Goldberg MS; Freeman GJ; Rodig SJ; Davison JM; Bass AJ
    Cancer Immunol Res; 2015 Oct; 3(10):1123-1129. PubMed ID: 26081225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia.
    Wang DH; Clemons NJ; Miyashita T; Dupuy AJ; Zhang W; Szczepny A; Corcoran-Schwartz IM; Wilburn DL; Montgomery EA; Wang JS; Jenkins NA; Copeland NA; Harmon JW; Phillips WA; Watkins DN
    Gastroenterology; 2010 May; 138(5):1810-22. PubMed ID: 20138038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to TNF-α Is Increasing Along with the Progression in Barrett's Esophagus.
    Chemnitzer O; Götzel K; Maurer L; Dietrich A; Eichfeld U; Lyros O; Jansen-Winkeln B; Hoffmeister A; Gockel I; Thieme R
    Dig Dis Sci; 2017 Dec; 62(12):3391-3401. PubMed ID: 29086334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Origins of Metaplasia in Barrett's Esophagus: Is this an Esophageal Stem or Progenitor Cell Disease?
    Zhang W; Wang DH
    Dig Dis Sci; 2018 Aug; 63(8):2005-2012. PubMed ID: 29675663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
    Feith M; Stein HJ; Mueller J; Siewert JR
    Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barrett's esophagus: recent insights into pathogenesis and cellular ontogeny.
    Kapoor H; Agrawal DK; Mittal SK
    Transl Res; 2015 Jul; 166(1):28-40. PubMed ID: 25701368
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Fang HY; Münch NS; Schottelius M; Ingermann J; Liu H; Schauer M; Stangl S; Multhoff G; Steiger K; Gerngroß C; Jesinghaus M; Weichert W; Kühl AA; Sepulveda AR; Wester HJ; Wang TC; Quante M
    Clin Cancer Res; 2018 Mar; 24(5):1048-1061. PubMed ID: 29208671
    [No Abstract]   [Full Text] [Related]  

  • 16. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of inflammation-metaplasia-adenocarcinoma sequence and inflammatory microenvironment in esophageal carcinogenesis using surgical rat models.
    Miyashita T; Tajima H; Shah FA; Oshima M; Makino I; Nakagawara H; Kitagawa H; Fujimura T; Harmon JW; Ohta T
    Ann Surg Oncol; 2014 Jun; 21(6):2012-9. PubMed ID: 24526548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
    Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
    Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of Barrett's Esophagus and Esophageal Carcinoma.
    Fabian T; Leung A
    Surg Clin North Am; 2021 Jun; 101(3):381-389. PubMed ID: 34048759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
    Majka J; Rembiasz K; Migaczewski M; Budzynski A; Ptak-Belowska A; Pabianczyk R; Urbanczyk K; Zub-Pokrowiecka A; Matlok M; Brzozowski T
    J Physiol Pharmacol; 2010 Aug; 61(4):409-18. PubMed ID: 20814068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.